G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Carcinoma, Ductal, Breast|Breast Cancer|Breast Neoplasm
Interventions: DRUG: G1T38|DRUG: Fulvestrant
Sponsor: G1 Therapeutics, Inc.